Syndax Pharmaceuticals (SNDX) Downgraded by TheStreet

TheStreet downgraded shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a c- rating to a d rating in a research report report published on Friday.

A number of other equities research analysts also recently weighed in on the stock. BidaskClub downgraded shares of Syndax Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, April 11th. ValuEngine raised shares of Syndax Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, March 20th. Morgan Stanley cut their price target on shares of Syndax Pharmaceuticals from $25.00 to $24.00 and set an overweight rating for the company in a report on Wednesday, March 14th. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, January 23rd. Finally, B. Riley reissued a buy rating and issued a $40.00 price target on shares of Syndax Pharmaceuticals in a report on Thursday, January 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $23.86.

How to Become a New Pot Stock Millionaire

Shares of SNDX opened at $10.76 on Friday. The stock has a market capitalization of $282.05, a P/E ratio of -3.71 and a beta of 1.04. Syndax Pharmaceuticals has a 52-week low of $7.41 and a 52-week high of $15.43.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, March 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.04). Syndax Pharmaceuticals had a negative net margin of 2,884.34% and a negative return on equity of 63.51%. The company had revenue of $1.19 million during the quarter, compared to the consensus estimate of $0.75 million. The company’s revenue was up 290.2% on a year-over-year basis. equities analysts forecast that Syndax Pharmaceuticals will post -3.52 earnings per share for the current fiscal year.

In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 7,500 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $15.00, for a total value of $112,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 24.10% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. BVF Inc. IL purchased a new stake in Syndax Pharmaceuticals during the fourth quarter valued at about $28,326,000. Millennium Management LLC lifted its stake in Syndax Pharmaceuticals by 18.9% during the fourth quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock valued at $4,525,000 after buying an additional 82,256 shares in the last quarter. Geode Capital Management LLC lifted its stake in Syndax Pharmaceuticals by 17.4% during the fourth quarter. Geode Capital Management LLC now owns 153,483 shares of the company’s stock valued at $1,344,000 after buying an additional 22,803 shares in the last quarter. Crestline Management LP lifted its stake in Syndax Pharmaceuticals by 55.3% during the fourth quarter. Crestline Management LP now owns 83,139 shares of the company’s stock valued at $728,000 after buying an additional 29,607 shares in the last quarter. Finally, State Street Corp lifted its stake in Syndax Pharmaceuticals by 32.8% during the second quarter. State Street Corp now owns 81,327 shares of the company’s stock valued at $1,137,000 after buying an additional 20,106 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This news story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2018/04/17/syndax-pharmaceuticals-sndx-downgraded-by-thestreet.html.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply